SWP
SPRY icon

Strategic Wealth Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Strategic Wealth Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160 Hold
20
– – ﹤0.01% 1376
2026
Q1 		$161 Hold
20
– – ﹤0.01% 1388
2025
Q4 		$233 Buy
+20
New +$195 ﹤0.01% 1378

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Strategic Wealth Partners's SPRY Position: Q2 2026 in Review

Strategic Wealth Partners held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 20 shares worth $160. The position accounts for ﹤0.01% of the portfolio, ranked #1376.

Strategic Wealth Partners first reported a position in SPRY in Q4 2025 and has held it in 3 quarters since. The position peaked at $233 in Q4 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Strategic Wealth Partners held 20 shares of ARS Pharmaceuticals worth $160 as of Q2 2026.
  • Strategic Wealth Partners left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Strategic Wealth Partners's portfolio in Q2 2026, its #1376 holding.
  • Strategic Wealth Partners first reported a position in ARS Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Strategic Wealth Partners's ARS Pharmaceuticals position peaked at $233 in Q4 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Strategic Wealth Partners's 13F filing for Q2 2026, filed 12 Aug 2026.